In Week of Mar 28, 2026, Apollo Hospitals Enterprise Ltd (Hospitals) is outperforming Nifty 500 with +17.1% relative strength. Fundamentals: Average. On a 6-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: New hospitals reaching profitability faster with focused ramp-up strategy
Impact: +₹5000 Cr revenue
“We are very very focused on quickly ramping up to profitability by [new hospitals]”
What: Cardiac and oncology specialties delivering 16% YoY revenue growth
Impact: +₹2000 Cr revenue
“These specialties remain a key growth engine for us and delivered a robust 16% year-on-year revenue growth”
What: Apollo 24/7 GMV at ₹525 cr, up 28% YoY with improving economics
Impact: +₹350 Cr revenue
“Cash losses in the digital business were at rupees 29 cr the lowest in any quarter by far”
Earnings deceleration risks from management commentary
Trigger: New hospital ramp-up phase
Impact: -150 bps margin impact
Management view: We are carefully balancing the EBIT deterioration in our new hospitals with how we are managing our existing hospitals
Monitor: New hospital EBITDA contribution
Trigger: Insurance payment delays
Impact: -50 bps margin impact
Management view: Because of this insurance mismatch that has happened otherwise we very much on course
Monitor: Insurance receivables days
Key quotes from recent conference calls
“Group-wide occupancy at 67% in quarter 3 FY26 — Management”
“We are carefully balancing the EBIT deterioration in our new hospitals with how we are managing our existing hospitals — Management”
“Insurance and cash patients together accounted for 83% of in patient hospital revenues for quarter 3 FY26 underscoring the strength and resilience of our payer mix — Management”
“I think where we stand today at Q3 annualized number we are roughly at 20,000 crores and we've got five more quarters to hit the run rate of about 25,000 cr which is roughly about 25% from now to there — Management”
Forward-looking targets from management for Next 5 quarters to Q4 FY27
Revenue Growth Target
25%
Implied PAT Growth
20%
Key Milestones
• 25,000 cr annualized revenue run rate by Q4 FY27
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +17% | +14% | Stable |
| PAT (Net Profit) | +36% | +11% | Stable |
| OPM | 15.0% | +100 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Apollo Hospitals Enterprise Ltd's latest quarterly results (Dec 2025) show
Apollo Hospitals Enterprise Ltd's profit is growing with an stable trend.
Apollo Hospitals Enterprise Ltd's revenue growth trend is stable.
Apollo Hospitals Enterprise Ltd's operating margin is expanding.
Apollo Hospitals Enterprise Ltd's long-term compounding rates
Apollo Hospitals Enterprise Ltd's earnings growth is stable with positive momentum on a sequential basis.
Apollo Hospitals Enterprise Ltd's trailing twelve month (TTM) performance
Apollo Hospitals Enterprise Ltd appears slightly undervalued based on our fair value analysis.
Apollo Hospitals Enterprise Ltd's current PE ratio is 59.8x.
Apollo Hospitals Enterprise Ltd's current PE is 59.8x.
Apollo Hospitals Enterprise Ltd's price-to-book ratio is 11.9x.
Apollo Hospitals Enterprise Ltd is rated Average with a fundamental score of 50.32/100. This score is calculated from objective financial metrics
Apollo Hospitals Enterprise Ltd has a debt-to-equity ratio of N/A.
Apollo Hospitals Enterprise Ltd's return ratios over recent years
Apollo Hospitals Enterprise Ltd's operating cash flow is positive (FY2025).
Apollo Hospitals Enterprise Ltd's current dividend yield is 0.25%.
Apollo Hospitals Enterprise Ltd's shareholding pattern (Dec 2025)
Apollo Hospitals Enterprise Ltd's promoter holding has remained stable recently.
Apollo Hospitals Enterprise Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.
Apollo Hospitals Enterprise Ltd is an established outperformer with 6 weeks of consecutive Nifty 500 outperformance.
Apollo Hospitals Enterprise Ltd has 3 key growth catalysts identified from recent earnings analysis
Apollo Hospitals Enterprise Ltd has 2 key risks worth monitoring
In Q3 FY26, Apollo Hospitals Enterprise Ltd's management highlighted
Apollo Hospitals Enterprise Ltd's management has provided the following forward guidance for Next 5 quarters to Q4 FY27
Based on quantitative research signals, here is why Apollo Hospitals Enterprise Ltd may be worth studying
Apollo Hospitals Enterprise Ltd investment thesis summary:
Apollo Hospitals Enterprise Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
